Deerfield Management On Fund Building, Philanthropy, And Optimism For The Future
Executive Summary
Andrew ElBardissi, partner on Deerfield Management’s medical technologies team, spoke to In Vivo sister publication Medtech Insight about the fund’s investment strategy, the changing face of medtech, and how investment in the life sciences sector will continue to change post-COVID.
You may also be interested in...
Investor Eye: What's Changing In Medtech Deal Making As We Approach The End Of 2022?
Kristen Pothier, global lead of KPMG’s health care and life sciences advisory service, spoke to Medtech Insight about the current deal making climate, and how it impacts the diagnostics sector.
CobiCure Will Develop Cardiac Devices For Children, Sans Profit Motive
CobiCure is pursuing a non-profit approach to the development of cardiac devices for underserved patient populations.
How Ochre Bio Bagged Boehringer For Its RNA-Based Regenerative MASH Therapies
UK-based Ochre Bio has signed its first major deal with Boehringer Ingelheim. Scrip talked to its co-founder and CEO, Jack O’Meara, about its human tissue-based drug discovery platform, its resulting RNA platform for liver disease and how the fledgling drug company's early work mirrored that seen in diagnostics.